Regulatory Fine Points: What Research Sites Need to Do for Part 11 Compliance
To maintain Part 11 compliance, research sites must validate electronic systems storing FDA-regulated records, safeguarding data integrity and accuracy.
To maintain Part 11 compliance, research sites must validate electronic systems storing FDA-regulated records, safeguarding data integrity and accuracy.
In a recent webinar, Advarra experts Constance Cullity and Michele Russell-Einhorn presented FDA Inspections of Clinical Investigators: Understanding the Process
In a recent blog, we described the complexity and uniqueness of Phase I clinical trials, outlining the fact that some
A key element to successful study startup is identifying efficiencies to help meet critical milestones. Engaging with research compliance experts
Explore Advarra’s Study Activation Report to uncover roadblocks, survey findings, and solutions to streamline clinical trial activation at sites.
Decentralization is one arrow in the quiver to modernize clinical trials.[1] Yet, owing to the varied approaches and possible components
In the final part of the three-part FDA inspection readiness series, we will go into detail about what to expect
In our previous blog, FDA Inspection Readiness: Preparing for an Inspection we reviewed how to prepare for a Food and
We are now almost a year into the COVID-19 pandemic, and you may be asking whether your clinical trials remained
Informed consent isn’t just a formality—it’s an evolving process that safeguards participant autonomy and enhances study integrity from start to finish.
In a recent webinar, Advarra regulatory experts presented on the topic titled Institutional Responsibilities Under a Federalwide Assurance (FWA). Our
In a recent webinar, James Riddle, Shannon Roznoski, and Stuart Cotter of Advarra presented Regulatory Fine Points: Exploring 21 CFR Part